Genetic and Clinical Features in TP53-Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next-Generation Sequencing Data.

The recent fifth edition of World Health Organization and International Consensus Classification in 2022 recognized TP53-mutated myelodysplastic neoplasms (MDS) as a distinct entity requiring multi-hit classification. Literatures indicate that TP53 variant alle frequency (VAF) correlates with clinical outcomes. However, comprehensive studies that characterize the full mutation landscape and clinical correlations in Asian populations are still limited. This research aims to elucidate the mutation

本文自动抓取自 PubMed，原文链接：Genetic and Clinical Features in TP53-Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next-Generation Sequencing Data.

原文发布日期：2026-06-01